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Abstract
Background. The evaluation of the peritoneal transport
characteristics is mandatory in peritoneal dialysis (PD)
patients. This is usually performed in routine clinical prac-
tice with a peritoneal equilibration test (PET) using
conventional dialysates, with low pH and high glucose
degradation product (GDP) concentrations. An increasing
proportion of patients are now treated with biocompatible
dialysates, i.e. with physiological pH and lower GDP con-
centrations. This questions the appropriateness to perform
a PET with conventional solutions in those patients. The
aim of our study is to compare the results of the PET using
biocompatible and conventional dialysates, respectively.
Methods. Nineteen stable PD patients (13 males, 6
females; mean age: 67.95 ± 2.36 years, mean body surface
area: 1.83 ± 0.04 m2, dialysis vintage: 2.95 ± 0.19 years)
were included, among which 10 were usually treated with
biocompatible and 9 with conventional solutions. Two
PETs were performed, within a 2-week interval, in each
patient. PET sequence (conventional solution ﬁrst or bio-
compatible solution ﬁrst) was randomized in order to
avoid ‘time bias’. Small (urea, creatinine and glucose),
middle (beta-2-microglobulin) and large molecules’
(albumin and alpha-2-macroglobulin) dialysate/plasma
(D/P) concentration ratios and clearances were measured
during each PET. Ultraﬁltration (UF) and sodium ﬁltration
were also recorded. Results of both tests were compared
by the Wilcoxon paired test.
Results. No statistical difference was found between both
dialysates for small molecule transport rates or for sodium
ﬁltration and UF. However, a few patients were not simi-
larly classiﬁed for small-solute transport characteristics
within the PET categories. Beta-2-microglobulin
and albumin D/P ratios at different time points of the PET
were signiﬁcantly higher with the biocompatible, when
compared with the conventional, solutions: 0.10 ± 0.03
versus 0.08 ± 0.02 (P < 0.01) and 0.008 ± 0.003 versus
0.007 ± 0.003 (P = 0.01), respectively. A similar difference
was also observed for beta-2-microglobulin that was
higher with biocompatible dialysates (1.04 ± 0.32 versus
0.93 ± 0.32 mL/min, respectively).
Conclusion. Peritoneal transport of water and small
solutes is independent of the type of dialysate which is
used. This is not the case for the transport of beta-2-micro-
globulin and albumin that is higher under biocompatible
dialysates. Vascular tonus modiﬁcation could potentially
explain such differences. The PET should therefore always
be carried out with the same dialysate to make longitudinal
comparisons possible.
Keywords: albumin; beta-2-microglobulin; biocompatible solutions;
peritoneal dialysis; peritoneal equilibration test
Introduction
The evaluation of the peritoneal transport characteristics
is of major clinical importance in peritoneal dialysis (PD)
patients [1–3]. This is usually performed in routine clini-
cal practice with a peritoneal equilibration test (PET) [4].
The original procedure, performed with a single 4-h dwell,
classically uses conventional solutions with a 2.27%
glucose concentration. Also, Parikova et al. [18] documen-
ted an absence of difference between both types of dialy-
sates for the peritoneal transport rates of middle and large
molecules. Dialysate/plasma (D/P) ratios are then calcu-
lated to evaluate the peritoneal solute transport rate and
patients are thereafter categorized, according to D/P creati-
nine ratios, into four different transport patterns: slow,
slow average, fast average and fast. Several studies have
shown the interest of performing PET with hypertonic
3.86% glucose solutions to improve information on ultra-
ﬁltration (UF) and mainly on aquaporin-mediated free
water transport [5–11].
Conventional dialysates are hypertonic glucose sol-
utions ranging between 1.36 and 3.86% with an acidic pH
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(5.5) and lactate, as buffer agent. Despite the low pH of
conventional solutions, high levels of glucose degradation
products (GDPs) are produced. Several studies have
shown that high GDP concentrations, mainly 3-deoxyglu-
cose, methylglyoxal and glyoxal, increase angiogenesis,
submesothelial ﬁbrosis, which may eventually lead to
dialysis failure. The introduction of new dialysates with
bicompartimented bags has decreased the concentration of
GDPs as glucose is conserved in a highly acidic solution.
The neutral pH (7.4) and the mix of bicarbonate and
lactate as buffer agents decrease abdominal pain and dis-
comfort during dialysis. A beneﬁt of the new solutions
has also been demonstrated in terms of better protection
of the peritoneal membrane integrity reﬂected by the
CA125 level [12–14], but not for the preservation of the
residual renal function [15], when compared with conven-
tional dialysates.
A number of recent controlled observational follow-up
studies comparing the effect of biocompatible and con-
ventional dialysates on small solute and water transport
(reviewed in ref. [16]) also showed discordant results. As
a matter of debate, La Milia et al. [17] postulated that bio-
compatible solutions could inﬂuence UF as dissociation of
sodium chloride is incomplete at normal pH, with a sub-
sequent negative effect of lower concentration of ionized
sodium on water transport induced by crystalloid osmosis.
Also, Parikova et al. [18] documented an absence of
difference between both types of dialysates for the trans-
port rates of peritoneal middle and large molecules.
An increasing number of patients are now treated with
new biocompatible solutions, because of the above-
mentioned theoretic advantages, while PET might still be
performed using conventional dialysates. It is not known
whether this approach has a detrimental effect on the
interpretation of the PET results.
The aim of our study was to compare, in the same
patients, the results of two consecutive PETs using a 3.86%
conventional low pH/high GDP glucose dialysate and a
3.86% normal pH/low GDP glucose dialysate, or vice-versa.
Materials and methods
Nineteen stable PD patients (13 males, 6 females; mean age:
67.95 ± 2.36 years, mean body surface area (BSA): 1.83 ± 0.04 m2,
dialysis vintage: 2.95 ± 0.19 years) were included, among which 10 were
usually treated with biocompatible and 9 with conventional solutions.
They had all been on regular automated PD (APD) for at least 3 months.
Their medical condition was stable without active inﬂammation (C-reactive
protein <10 mg/L) and they had been free of acute abdominal pathology
(including peritonitis) for at least 3 months. The recommended 3.86%
glucose modiﬁed PET was used according to the International Society for
Peritoneal Dialysis (ISPD) recommendations [19].
Two PETs were performed in each group within a 2-week interval.
One test was performed with the conventional dialysate (Dianeal®
Baxter) and the other with the new biocompatible dialysate (Physioneal®
Baxter). PET sequence (conventional solution ﬁrst or biocompatible sol-
ution ﬁrst) was randomized in order to avoid ‘time bias’. The same sol-
ution of the PET was used the night before the test to exclude putative
solute transport changes related to the dialysate itself. Blood samples
were drawn after 120 min, as recommended [4]. A dialysate sample
(10 mL) was taken at the start of the test and after 60, 120 and 240 min,
as previously described. Net UF, i.e. the net difference between dialysate
volume efﬂuent and volume infused, was recorded.
Small, middle and large molecule measurements
Serum measurements of urea, creatinine, glucose, sodium and phosphate
were performed using the routine laboratory technique on a Modular
analyser (Roche Diagnostic). The Jaffé method was used for creatinine
determination, and the results were corrected for the interference with
high glucose levels. Sodium measurements have been made by indirect
ion-selective electrode. Albumin, alpha-2-macroglobulin and beta-2-
microglobulin in both serum and dialysate were measured by immunone-
phelometry on the BN II analyser (Siemens).
Calculations
The D/P ratios of small, middle and large molecules (urea, creatinine,
phosphate, albumin, beta-2-microglobulin and alpha-2-macroglobulin)
were calculated at speciﬁc times (60, 120 and 240 min, respectively). The
ratio of dialysate glucose concentrations at speciﬁc ‘t’ (60, 120 and 240
min) times, when compared with the glucose concentration of the instilled
dialysate (D/D0), was also calculated.
D/P sodium was measured at the beginning of the PET and at 1 h.
Sodium ﬁltration was deﬁned as the difference between D/P sodium
[corrected for sodium diffusion using mass transfer area coefﬁcient
(MTAC) creatinine] at 1 h when compared with its value at the initiation
of the test [20].
The dialysate clearances of different molecules (urea, creatinine,
phosphate, albumin, beta-2-microglobulin and alpha-2-macroglobulin)
were calculated using the following formula:
Clearance ½solute
¼ ½Solute dialysate at Hour 4 Effluent volume½Solute serum 240
where [solute] represents the solute concentration.
Sodium removal (NaR) was calculated as follows:
NaRðmmolÞ¼ ½volume dialysate outðLÞ
 ½Nadialysate outðmmol=LÞ ½volume dialysate inðLÞ
 ½Nadialysate inðmmol=LÞ
The MTAC of creatinine and urea was calculated according to Waniewski
et al. [21, 22].
Statistical analysis
This is a multicentre prospective study where results are expressed as
mean values ± 1 standard deviation (SD) and also as median values with
25–75 conﬁdence intervals (CIs). PET results have been compared by
the Wilcoxon paired test. Graphics error bars are expressed in standard
error of the mean (SEM). The statistical signiﬁcance level was set to
0.05.
Ethical considerations
PET is a part of the normal procedure of care for PD patients. All
patients gave written informed consent for the supplementary PET and
the additional sample collection of blood and dialysate. The study design
was approved by the local ethics committee.
Results
The PET results using both dialysates are presented inde-
pendently of patient usual treatment.
Ultraﬁltration, sodium removal and small solutes removal
There was no statistical difference between both solutions
in terms of net UF at the end of the test (240 min):
340 ± 258 versus 386 ± 233 mL with biocompatible and
conventional dialysates, respectively (Table 1). Sodium
ﬁltration and sodium removal at 240 min are identical
between solutions.
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D/P ratios for urea and creatinine at 240 min and for
D240/D0 glucose were not statistically different between
PETs. The respective MTACs and clearances were also
virtually similar.
However, the categorization of the peritoneal transport
rate was slightly different in a few patients, as illustrated
in Figure 1 according to the type of dialysate which was
used for the test.
Middle molecule transport [beta-2-microglobulin—
molecular weight: 11 800 Da]
The D/P ratio for beta-2-microglobulin at 240 min was
signiﬁcantly greater with biocompatible solutions:
0.109 ± 0.037 versus 0.094 ± 0.032 with biocompatible
and conventional dialysates, respectively (P < 0.01;
Table 2). A statistical difference was already observed for
the 120-min ratios (Figure 2). A similar difference was
observed for beta-2-microglobulin clearance (1.04 ± 0.32
for biocompatible versus 0.93 ± 0.32 mL/min for conven-
tional dialysates; P < 0.05).
Large molecule transport (albumin— molecular weight:
69 kDa, alpha-2-macroglobulin— molecular weight: 725
kDa)
The D/P albumin ratio was statistically higher with bio-
compatible solutions PET 0.008 ± 0.003 in biocompatible
dialysates versus 0.007 ± 0.003 in conventional dialysates
(P = 0.01; Figure 3 and Table 2). There was also a same
trend for D/P alpha-2-macroglobulin and for both mol-
ecules clearances, although it did not reach statistical
signiﬁcance.
Discussion
The evaluation of water and solute peritoneal transport
rates is of major clinical importance in PD patients. The
objective of our study was to compare the results of per-
itoneal transport rates consecutively assessed, in the same
patients, with conventional and biocompatible dialysates.
A signiﬁcantly greater transport rate for beta-2-micro-
globulin and albumin, but not for alpha-2-macroglobulin,
was observed when biocompatible solutions were used.
The observation for the latter molecule could probably be
accounted for by its large molecular size and the relatively
‘short’ PET duration that does not allow signiﬁcant differ-
ences to appear. By contrast, there was no statistical
difference between both dialysates for small molecule
transport rates, sodium ﬁltration, sodium removal and UF.
Similar results, although less signiﬁcant than those of
the D/P ratios, were also obtained for middle and large
molecule clearances. The ﬁnding that D/P albumin
reached signiﬁcance, but not albumin clearance, could
potentially be explained by the PET duration: longer ex-
change time, i.e. over 4 h, might have led to signiﬁcant
results.
The analysis of the various transport categories, based
on the initial description of Twardowski et al. [4], also
showed some differences according to the type of dialy-
sate which is used: there was a higher proportion of ‘fast
average’ and no case of ‘small’ transport categories when
Table 1. Results of UF, sodium ﬁltration, sodium removal and small molecule D/P ratios, MTAC and clearances according to both types of dialysates
Biocompatible PET Conventional PET P-value
Mean [±SD] Median [CI 25–75] Mean [±SD] Median [CI 25–75]
UF240 (mL) 340 [±258] 340 [200–500] 386 [±233] 417 [250–507] NS
Sodium sieving −0.06 [±0.04] −0.051 [−0.079–0.034] −0.05 [±0.02] −0.043 [−0.063–0.031] NS
NaR240 (mmol) 32.9 [±31.3] 31.9 [7.2–58.6] 38.9 [±28.6] 35.7 [27.5–55.4] NS
D/P240 urea 0.92 [±0.05] 0.93 [0.87–0.95] 0.91 [±0.05] 0.92 [0.86–0.95] NS
D/P240 creatinine 0.691 [±0.089] 0.68 [0.65–0.74] 0.677 [±0.094] 0.68 [0.62–0.73] NS
D240/D0 glucose 0.33 [±0.08] 0.33 [0.27–0.39] 0.31 [±0.07] 0.29 [0.25–0.34] NS
MTAC creatinine (mL/min) 8.9 [±3.0] 8.5 [6.8–11.1] 8.7 [±2.7] 8.7 [6.8–10.7] NS
MTAC creatinine/BSA (mL/min/m2) 4.9 [±1.6] 4.8 [3.7–6.2] 4.8 [±1.5] 4.9 [3.5–5.9] NS
MTAC urea (mL/min) 23.5 [±7.1] 23.1 [17.3–28.1] 22.5 [±6.1] 23.4 [16.8–26.8] NS
MTAC urea/BSA (mL/min/m2) 12.8 [±3.8] 12.9 [10.3–14.6] 12.5 [±3.9] 12.8 [9.2–14.1] NS
Clearances (mL/min)
Urea 9.0 [±0.99] 9.0 [8.4–9.8] 9.0 [±1.01] 8.9 [8.5–9.7] NS
Creatinine 6.7 [±0.88] 7.0 [5.8–7.4] 6.7 [±1.01] 6.7 [6.2–7.3] NS
Results are expressed as mean values ± 1 SD and median values with 25–75 CIs. NS, not signiﬁcant.
Fig. 1. Categorization of the peritoneal transport rate for small solutes
according to the type of dialysate which was used for the test. F, fast;
FA, fast average; SA, slow average; S, slow; transport rate status. Two
and four patients with an S and an SA transport rate status with
conventional dialysates are now categorized as SA and FA transporters,
respectively, with biocompatible dialysates.
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biocompatible solutions were used. These differences
could have a signiﬁcant impact on PD prescription in
routine clinical practice as, for instance, APD prescription
is based on those transport categories [23].
In summary, our results suggest that biocompatible sol-
utions seem to increase the peritoneal transport rates of
beta-2-microglobulin and albumin, at least, during an
acute exposition, as is the case during a PET, an obser-
vation which is different, as mentioned above, from that
previously reported by Parikova et al. Indeed, those
authors failed to ﬁnd any inﬂuence of the type of sol-
utions on transperitoneal solute transport for small
solutes, as in our study, and also for middle and large
molecule clearances, as evaluated by a standard peritoneal
analyses with an intraperitoneal injection of dextran 70
[18]. Given the absence of deleterious effect of dextran
70 on peritoneal transport rate assessment [24], we cannot
explain those discordant results. Since both our studies
rely on a small number of patients and because D/P ratios
are not available in the study by Parikova et al., our ﬁnd-
ings need to be re-evaluated and veriﬁed in a larger
cohort of patients.
We have to acknowledge several limitations for the
interpretation of the results obtained in the present study:
the small sample size, the usual well-known PET limit-
ations (interference of high glucose concentration with
creatinine determination, difﬁculty in sodium measure-
ment, interference of residual volume etc.), the higher
D/P albumin ratio at time 0 for the biocompatible sol-
utions and the absence of randomization of the type of
dialysate which was routinely used.
The results we have observed might have been obtained
‘by chance’. Now, is there a rationale for a higher transport
rate for beta-2-microglobulin and albumin during the PET
using biocompatible dialysates? Although physiological
mechanisms involved in the peritoneal transport rate of
macromolecules still remain ill-deﬁned, the main hypoth-
esis leads to some peritoneal vascular tonus variations
with speciﬁc acute vasodilatory action of the biocompati-
ble dialysate within the peritoneal vasculature. A lower
content in GDPs in the biocompatible dialysates might
paradoxically induce a higher local exposition to nitric
oxide [25–27], leading to an increased vascular ﬂow rate,
as recently documented for albumin transport in mice
lacking endothelial caveolae [28]. Although this would be
an attractive hypothesis, it still has to be reconciled with
Table 2. Results of beta-2-microglobulin, albumin and alpha-2-macroglobulin D/P ratios and clearances according to both types of dialysate
‘Biocompatible’ PET ‘Conventional’ PET P-value
Mean [±SD] Median [CI 25–75] Mean [±SD] Median [CI 25–75]
D/P240 beta-2-microglobulin 0.109 [±0.037] 0.099 [0.088–0.138] 0.094 [±0.032] 0.087 [0.072–0.118] <0.01
D/P240 albumin 0.0078 [±0.0029] 6.8 [5.8–10.7] 0.0066 [±0.0026] 6.4 [4.6–8.9] 0.01
D/P240 alpha-2-macroglobulin 0.0009 [±0.0013] 0.00 [0.00–1.46] 0.0007 [±0.0013] 0.00 [0.00–1.22] NS
Clearances (mL/min)
Beta-2-macroglobulin 1.04 [±0.32] 0.97 [0.90–1.22] 0.93 [±0.32] 0.82 [0.75–1.11] <0.05
Albumin 0.075 [±0.026] 0.073 [0.054–0.099] 0.066 [±0.027] 0.065 [0.045–0.083] NS
Alpha-2-macroglobulin 0.011 [±0.010] 0.007 [0.005–0.014] 0.010 [±0.011] 0.005[0.004–0.009] NS
Results are expressed as mean values ± 1 SD and median values with 25–75 CIs. NS, not signiﬁcant.
Fig. 3. D/P albumin comparison between biocompatible (black circle)
and conventional (open circle) solution PET. Results are expressed as
mean values ± 1 SEM. *P < 0.05; **P < 0.01.
Fig. 2. D/P beta-2-microglobulin comparison between biocompatible
(black circle) and conventional (open circle) solution PET. Results are
expressed as mean values ± 1 SEM. *P < 0.05; **P < 0.01.
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some preclinical ﬁndings reported by Mortier et al. [29],
in animals. Those authors showed that conventional, but
not biocompatible, solutions had important vasoactive
effect on peritoneal microcirculation that had been attribu-
ted to their GDP and lactate content. Finally, as our
patients were not randomized to be routinely given con-
ventional or biocompatible dialysates, individual reduced
selectivity of the endothelial glycocalix to larger solute
transport or differences in the peritoneal interstitial tissue
might also explain the differences observed between both
types of dialysates.
More clinical studies, including a larger number of
naïve and prevalent PD patients, are therefore necessary
to better differentiate the intraperitoneal haemodynamic
changes related to the use of both types of dialysates.
Conclusion
The evaluation of the peritoneal transport rate of beta-2-
microglobulin and albumin is dependent on the type of
dialysate which is used. Higher peritoneal transport rates
are observed under biocompatible, when compared with
conventional dialysates. Vascular tonus modiﬁcation
could potentially explain such differences. The PET
should therefore always be carried out with the same dia-
lysate to allow longitudinal comparisons.
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